Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 19.61
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers.
Data is available to registered users only
Target Price
The average target price of AMRN is 11 and suggests 43% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decre
Data is available to registered users only
